Allogene Therapeutics Overview

Allogene Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for ALLO.

Quarterly EBIT

-$46.09M

↑ 22.64% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$205.81M

↑ 19.98% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin